Abstract
Purpose: Females with in-hospital treatment for acute cystitis (AC) or pyelonephritis may benefit from catheterization at admission. Methods: All female patients with AC or pyelonephritis requiring in-hospital treatment at University Hospital Frankfurt (2004–2019) were retrospectively analyzed. Logistic regression models were used to predict the catheter value. Results: Of 310 female patients, 40% harbored AC versus 60% pyelonephritis, of whom 62% and 74% received a catheter at admission: C-reactive protein (CRP) and white blood count (WBC) were significantly elevated in AC and pyelonephritis catheter versus no catheter patients (both p < 0.05). Time to CRP and WBC nadir did not differ between the AC catheter versus no catheter group (both p > 0.05). Conversely, time to CRP nadir was prolonged in pyelonephritis catheter patients. AC and pyelonephritis catheter patients exhibited a prolonged antibiotic treatment and length of stay (LOS, both p < 0.05). In multivariable analyses, CRP >5 ng/mL was a predictor for receiving a catheter in all patients. In AC, a positive urine culture and fever predicted, respectively, prolonged LOS or antibiotic treatment (all p < 0.05). Conclusion: Risk factors exist with regard to receiving a catheter and prolonged antibiotic treatment or LOS in females with AC or pyelonephritis. A catheter may not accelerate recovery or WBC nadir.
References
1.
Forsyth
VS
, Himpsl
SD
, Smith
SN
, Sarkissian
CA
, Mike
LA
, Stocki
JA
, Optimization of an experimental vaccine to prevent Escherichia coli urinary tract infection
. mBio
. 2020 28
;11
(2
):e00555-20
. .2.
Bonkat
G
, Cai
T
, Veeratterapillay
R
, Bruyère
F
, Bartoletti
R
, Pilatz
A
, Management of urosepsis in 2018
. Eur Urol Focus
. 2019 Jan
;5
(1
):5
–9
. .3.
Crivelli
JJ
, Zimmern
PE
. Vesicular cystitis: a chronic cystitis variant often unresponsive to antibiotics and electrofulguration
. Urol Int
. 2021
;105
(1–2
):131
–6
. .4.
Hooton
TM
. Clinical practice. Uncomplicated urinary tract infection
. N Engl J Med
. 2012 Mar 15
;366
(11
):1028
–37
. .5.
Ren
H
, Li
X
, Ni
ZH
, Niu
JY
, Cao
B
, Xu
J
, Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial
. Int Urol Nephrol
. 2017 Mar
;49
(3
):499
–507
. .6.
Rudrabhatla
P
, Deepanjali
S
, Mandal
J
, Swaminathan
RP
, Kadhiravan
T
. Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: a randomized non-inferiority trial
. PLoS ONE
. 2018 May 16
;13
(5
):e0197302
.7.
Schauer
I
, Al-Ali
BM
, Lüftenegger
W
, Madersbacher
S
, Eredics
K
. Is there a place for indwelling transurethral catheterization in women with febrile urinary tract infection? A prospective randomized trial
. World J Urol
. 2019 May
;37
(5
):849
–52
. .8.
Borgmann
H
, Struck
JP
, Mattigk
A
, Wenzel
M
, Pilatz
A
, Kranz
J
, Increased severe adverse outcomes and decreased emergency room visits for pyelonephritis: first report of collateral damage during COVID-19 pandemic in urology
. Urol Int
. 2021 Jan 6
;105
(3–4
):199
–205
. .9.
Wenzel
M
, Deuker
M
, Welte
MN
, Hoeh
B
, Preisser
F
, Homrich
T
, Catheter management and risk stratification of patients with in inpatient treatment due to acute epididymitis
. Front Surg
. 2020
;7
:609661
.10.
Bonkat
G
, Bartoletti
R
, Bruyère
F
, Cai
T
, Geerlings
SE
, Köves
B
, EAU guidelines on urological infections
. EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam The Netherlands 2020. 2020
. ISBN 978–94–92671–07–3.11.
R Core Team
. R: a language and environment for statistical computing
. 2017
. Available from: https://wwwr-projectorg2017.12.
Truzzi
JCI
, Almeida
FMR
, Nunes
EC
, Sadi
MV
. Residual urinary volume and urinary tract infection-when are they linked?
J Urol
. 2008 Jul
;180
(1
):182
–5
. .13.
Wagenlehner
FME
, Bjerklund Johansen
TE
, Cai
T
, Koves
B
, Kranz
J
, Pilatz
A
, Epidemiology, definition and treatment of complicated urinary tract infections
. Nat Rev Urol
. 2020 Aug 25
;17
(10
):586
–600
.14.
Saad
EJ
, Foia
E
, Finello
M
, Peñaranda
GE
, Suasnabar
DF
, Ellena Leon
MF
, Características epidemiológicas y microbiológicas de las infecciones urinarias no complicadas
. Rev Fac Cien Med Univ Nac Cordoba
. 2020 Aug 21
;77
(3
):155
–60
. .15.
Yasufuku
T
, Shigemura
K
, Arakawa
S
, Fujisawa
M
, Shigemura
K
, Yamashita
M
. Selection of first-line i.v. antibiotics for acute pyelonephritis in patients requiring emergency hospital admission
. J Infect Chemother
. 2011 Apr
;17
(2
):231
–7
. .16.
Hudson
C
, Mortimore
G
. The diagnosis and management of a patient with acute pyelonephritis
. Br J Nurs
. 2020 Feb 13
;29
(3
):144
–50
. .17.
Alpay
Y
, Aykin
N
, Korkmaz
P
, Gulduren
HM
, Caglan
FC
. Urinary tract infections in the geriatric patients
. Pak J Med Sci
. 2018 Jan–Feb
;34
(1
):67
–72
. .18.
Wijting
IEA
, Alsma
J
, Melles
DC
, Schipper
EM
, Schuit
SCE
. Urinary tract infections in a university hospital: pathogens and antibiotic susceptibility
. Neth J Med
. 2019
;77
(6
):210
–9
.19.
Tandoğdu
Z
, Bartoletti
R
, Cai
T
, Çek
M
, Grabe
M
, Kulchavenya
E
, Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013
. World J Urol
. 2016 Aug
;34
(8
):1193
–200
. .20.
Bruyère
F
, Azzouzi
AR
, Lavigne
J-P
, Droupy
S
, Coloby
P
, Game
X
, A multicenter, randomized, placebo-controlled study evaluating the efficacy of a combination of propolis and cranberry (Vaccinium macrocarpon) (DUAB®) in preventing low urinary tract infection recurrence in women complaining of recurrent cystitis
. Urol Int
. 2019
;103
(1
):41
–8
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
